Home/Pipeline/Vectorized-VX-765

Vectorized-VX-765

Metastatic Breast Cancer

ResearchActive

Key Facts

Indication

Metastatic Breast Cancer

Phase

Research

Status

Active

Company

Atlanthera

About Atlanthera

Atlanthera is a privately held, pre-clinical stage biotech company developing targeted therapies for bone and joint diseases. Its core technology involves conjugating active pharmaceutical ingredients (APIs) to proprietary hydroxybisphosphonate (HBP) vectors, enabling selective drug delivery to bone tissue to improve efficacy and reduce systemic toxicity. The company's pipeline includes candidates for osteosarcoma, osteoarthritis, and bone metastases, with its lead program nearing clinical entry. Atlanthera operates with a lean team and seeks partnerships for clinical development and commercialization.

View full company profile

Therapeutic Areas

Oncology Musculoskeletal Inflammation

Other Metastatic Breast Cancer Drugs

Drug	Company	Phase	Status
ZetaMAST (Zeta-MBC-005)	Zetagen Therapeutics	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
AURORA 2 Project Collaboration	Seqalis	Phase 2	Active
BPI-1178 (Eciruciclib)	Beta Pharma	Phase 3	Active
Herzuma®	Celltrion	Marketed	Approved
Eftilagimod alfa (efti)	Immutep	Phase IIb	Active (AIPAC-003)
(Z)-endoxifen	Atossa Therapeutics	Phase 1/2	Active (Presumed)
Bria-IMT™ + CPI	BriaCell Therapeutics	Phase 3	Active, Pivotal
Bria-OTS™ (Bria-BRES™)	BriaCell Therapeutics	Phase 1/2	Active, Recruiting